Actively Recruiting
Dimensional and Developmental Approach to Psychotic Episodes in Children and Adolescents: Impact on Clinical Management
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-23
200
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the wide range of schizophrenia and related psychotic disorders in children and adolescents aged 7 to 20 years. The study aims to identify clinical subgroups within this population and determine if these groups predict how patients respond to specific antipsychotic medications. This research involves collaboration across five sites in France and includes both clinical and biological data collection to better understand these conditions. The study involves comprehensive assessments including diagnostic interviews, developmental histories, cognitive testing, neuroimaging (MRI), and DNA analyses when patients and families agree. Participants will be monitored over time with follow-up visits scheduled at 1, 3, and 5 years to evaluate treatment responses and changes in clinical and cognitive status. These assessments include evaluating the Lifetime Dimensions of Psychosis Scale in children and adolescents. Participants will undergo medical and neuropsychological evaluations, speech and language assessments, and complete questionnaires related to psychosis symptoms. MRI scans and blood samples for genetic testing may be collected if consented. Researchers will track clinical changes, cognitive function, and treatment effects using specific scales during follow-up. The main outcome measured is the Lifetime Dimensions of Psychosis Scale at 4 months, with additional long-term evaluations up to 5 years. The total duration of participation spans several years with periodic assessments.
CONDITIONS
Brief Title
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children and young adults aged 7 to 20 years with onset of psychotic disorder between 7 and 17 years
- Hospitalized or receiving outpatient treatment for an acute or chronic psychotic episode
- Diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features according to DSM-V
- Written informed consent signed by parents or legal guardians and by the minor patient if possible
- Written informed consent signed by the patient if of legal age after clinical stabilization
- Health insurance coverage from Social Security (France), not AME coverage
- For genetic study participation, siblings must have at least two first-degree relatives with psychotic disorders in the family
- Written informed consent for genetic part signed by participating parents and siblings
- Health insurance coverage from Social Security (France) for genetic study participants, not AME coverage
You will not qualify if you...
- Moderate or severe intellectual disability (IQ less than 50)
- Psychoses caused by medical illness, medication effects, or substance abuse
- Diagnosis of bipolar disorder
- Patients under legal guardianship
- For neuroimaging only: any contraindications to MRI scanning
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 months
Participants undergo comprehensive medical, neuropsychological, and speech/language evaluations. A child psychiatrist completes the Lifetime Dimensions of Psychosis Scale - Child and Adolescent version. When agreed, MRI scans and blood samples for DNA analysis are collected.
1 baseline visit with possible MRI and blood draw
Duration - 5 years
Participants are monitored through follow-up visits to assess clinical response and treatment effects, including evaluation of treatment response to specific antipsychotic drugs.
Follow-up visits at 1, 3, and 5 years
Trial Site Locations
Total: 6 locations
1
Fondation Vallée, Gentilly
Gentilly, France, 94257
Not Yet Recruiting
2
CHRU de Lille
Lille, France, 59037
Not Yet Recruiting
3
CHU de Nice
Nice, France, 62000
Not Yet Recruiting
4
Pitié Salpétrière
Paris, France, 75013
Actively Recruiting
5
CHU de Rouen
Rouen, France, 76031
Not Yet Recruiting
6
CHU de Rouvray
Rouen, France, 76031
Not Yet Recruiting
Research Team
C
Claudine LAURENT-LEVINSON, M.D., Ph.D.
A
Anne BISSERY
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here